依达拉奉右莰醇结合rt-PA静脉溶栓治疗急性脑梗死的临床疗效及对患者血清氧化应激水平的影响  

Clinical efficacy of edaravone dexborneol combined with rt-PA intravenous thrombolysis in the treatment of acute cerebral infarction and its influence on serum oxidative stress level

作　　者：江齐群[1] 包青滢 JIANG Qi-qun;BAO Qing-ying(Nantong Second People's Hospital,Nantong 226002,China)

机构地区：[1]南通市第二人民医院,226002

出　　处：《中国实用医药》2023年第22期87-90,共4页China Practical Medicine

基　　金：2021年度南通市卫生健康委员会科研立项课题(项目编号:2018020323)。

摘　　要：目的分析依达拉奉右莰醇结合重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓治疗急性脑梗死(ACI)的临床疗效及对患者血清氧化应激水平的影响。方法选取124例ACI患者为研究对象,应用随机数字表法分为研究组与对照组,各62例。对照组给予rt-PA静脉溶栓治疗,研究组在对照组基础上加用依达拉奉右莰醇治疗。对比两组治疗前、治疗2周后血清氧化应激水平、日常生活能力、神经功能及治疗效果。结果治疗前,两组丙二醛(MDA)、血清谷胱甘肽过氧化物酶(GSH-Px)、超氧化物歧化酶(SOD)水平对比,差异无统计学意义(P>0.05)。治疗后,两组MDA水平低于本组治疗前,GSH-Px、SOD水平高于本组治疗前,且研究组MDA(6.20±1.35)nmol/ml低于对照组的(9.44±1.83)nmol/ml,GSH-Px(94.35±14.29)U/L、SOD(325.85±28.87)U/ml高于对照组的(73.38±13.06)U/L、(250.17±30.16)U/ml,差异有统计学意义(P<0.05)。治疗前,两组Barthel指数(BI)评分、美国国立卫生研究院卒中量表(NIHSS)评分对比,差异无统计学意义(P>0.05)。治疗后,两组BI评分高于本组治疗前,NIHSS评分低于本组治疗前,且研究组BI评分(68.29±5.19)分高于对照组的(54.12±5.03)分,NIHSS评分(5.86±1.47)分低于对照组的(9.58±1.96)分,差异有统计学意义(P<0.05)。研究组治疗总有效率95.16%高于对照组的82.26%,差异有统计学意义(P<0.05)。结论依达拉奉右莰醇结合rt-PA静脉溶栓治疗ACI能在较大程度上改善患者血清氧化应激水平与神经功能,提升其日常生活能力,提高患者整体疗效。To analyze the clinical efficacy of edaravone dexborneol combined with recombinant tissue-type plasminogen activator(rt-PA)intravenous thrombolysis in the treatment of acute cerebral infarction(ACI)and its influence on serum oxidative stress level.Methods A total of 124 patients with ACI were divided into study group and control group according to the random numerical table,with 62 patients in each group.The control group was treated with rt-PA intravenous thrombolysis,and the study group was treated with edaravone dexborneol on the basis of control group.The serum oxidative stress level,activities of daily living and neurological function before treatment and 2 weeks after treatment,and therapeutic effect were compared between the two groups.Results Before treatment,there was no statistically significant difference in the levels of malondialdehyde(MDA),glutathione peroxidase(GSH-Px)and superoxide dismutase(SOD)between the two groups(P>0.05).After treatment,MDA level in both groups were lower than that before treatment in this group,and GSH-Px and SOD levels were higher than those before treatment in this group;MDA of(6.20±1.35)nmol/ml in the study group was lower than that of(9.44±1.83)nmol/ml in the control group;GSH-Px of(94.35±14.29)U/L and SOD of(325.85±28.87)U/ml in the study group were higher than those of(73.38±13.06)U/L and(250.17±30.16)U/ml in the control group;the differences were statistically significant(P<0.05).Before treatment,there was no statistically significant difference in Barthel index(BI)score and National Institutes of Health Stroke Scale(NIHSS)score between the two groups(P>0.05).After treatment,BI score in both groups was higher than that before treatment in this group,and NIHSS score was lower than that before treatment in this group;BI score of(68.29±5.19)points in the study group was higher than that of(54.12±5.03)points in the control group;NIHSS score of(5.86±1.47)points in the study group was lower than that of(9.58±1.96)points in the control group;the differences were st

关 键 词：急性脑梗死 依达拉奉右莰醇 重组组织型纤溶酶原激活剂 静脉溶栓 血清氧化应激因子 日常生活能力 神经功能 

分 类 号：R743.3[医药卫生—神经病学与精神病学]